# US 2010/0136681 A1 · Cellular compositions for the treatment of kidney disease and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136681 A1
- Document ID: US20100136681A1
- Status: Published application
- Kind: A1
- Application number: 12/594,079
- Filed: 2008-03-18
- Published: 2010-06-03
- Earliest claimed: 2007-04-02
- Assignees: The General Hospital Corporation
- Inventors: M. Amin Arnaout
- Web page: https://patentgrep.com/patent/US20100136681A1

## CPC

- C12N 5/0687: {Renal stem cells; Renal progenitors}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

As described in more detail below, the present invention provides cellular compositions for the treatment or prevention of kidney disease. The invention is based, at least in part, on the discovery of a population of cortical peritubular Flk1- and Seal-expressing kidney cells having a high tubulogenic potential.

## Claims

### Claim 1

An isolated cell having tubulogenic potential, wherein the cell is Flk1 positive Sca1 positive and CD34 negative.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated cell of claim 1, wherein the cell is derived from adult or embryonic kidney.

### Claim 4 (depends on 2)

The isolated cell of claim 2, wherein the cell fails to express a polypeptide or expresses reduced levels of a polypeptide, wherein the polypeptide is selected from the group consisting of c-kit, CD34, CD45, CD31, and cytokeratin relative to a reference.

### Claim 5 (depends on 2)

The isolated cell of claim 2, wherein the cell is vimentin positive.

### Claim 6

An isolated adult kidney cell having tubulogenic potential, wherein the cell is Flk1 positive, Sca1 positive, vimentin positive and negative for c-kit, CD34, CD45, CD31, and cytokeratin.

### Claim 7 (depends on 6)

The isolated cell of claim 6, wherein the cell is selected as Flk1 positive, Sca1 positive, vimentin positive, c-kit negative, CD34 negative, CD45 negative, CD31 negative, or cytokeratin negative using an immunoassay.

### Claim 8 (depends on 7)

The isolated cell of claim 7, wherein the immunoassay is analytical flow cytometry.

### Claim 9

An isolated population of cells having tubulogenic potential, wherein at least 85% of the cells are Flk1 positive Sca1 positive and CD34 negative.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The isolated population of claim 9, wherein the population is derived from adult or embryonic kidney.

### Claim 12 (depends on 9)

The isolated population of claim 9, wherein at least 80% of the cells present in the population fail to express or express reduced levels of a polypeptide selected from the group consisting of c-kit, CD34, CD45, CD31, and cytokeratin.

### Claim 13 (depends on 9)

The isolated population of claim 9, wherein at least 80% of the cells present in the population are vimentin positive.

### Claim at position 14

14-42. (canceled)
